Do I need to take Imatinib (Gleevec) for three years or five years?

Imatinib, often called Gleevec, is a tyrosine kinase inhibitor mainly used to treat cancers such as chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). For patients with chronic myeloid leukemia, the treatment cycle of imatinib is not a uniformly fixed "three years" or "five years", but is comprehensively determined based on the patient's disease progression, molecular biological response, and tolerance to the drug.

In the treatment of CML, it is generally recommended that patients continue to take imatinib for at least 3 years or even longer. Clinical studies have shown that continuous use of imatinib for more than 5 years can significantly improve the molecular response rate and overall survival rate. After some patients achieve deep molecular remission (such as MR4.5) after more than 3 years of treatment, doctors will evaluate whether the drug trial can be discontinued. However, this situation requires strict monitoring. Once molecular relapse occurs after drug discontinuation, treatment needs to be resumed.

For patients with gastrointestinal stromal tumors (GIST), the duration of imatinib use depends on the risk of recurrence after surgery. Generally speaking, it is recommended that patients with medium and high risk take imatinib for at least 3 years after surgery. For patients with extremely high risk or patients with tumor recurrence/metastasis, doctors often recommend long-term or even lifelong medication to control disease progression.

In short, the treatment duration of imatinib is not generalized as "three years" or "five years", but is adjusted according to individualized conditions. Patients should regularly review blood indicators, bone marrow or imaging data while taking medication, and judge whether to continue taking medication or adjust the treatment plan under the guidance of a doctor. Do not stop medication or shorten the course of treatment on your own to avoid recurrence or progression of the disease.

Reference materials:https://www.gleevec.com/